Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer

Fig. 2

S6K1 amplification correlates with poor outcome in patients with breast cancer from public database. A The incidence of S6K1 genetic alteration in different cancer types from 10,967 samples, obtained by summarizing the data of TCGA PanCancer Atlas Studies on cBioPortal. B The mRNA level of S6K1 gene in TCGA patients with various cancers are reported as median FPKM (Fragment Per Kilobase of exon per Million reads), downloaded from the Human Protein Atlas. Data are represented as the mean ± SEM. P value was calculated by Kruskal-Wallis test. ****, P < 0.0001. C The S6K1 locus was substantially amplified in breast cancer samples from oestrogen receptor (ER) positive subtypes based on cBioPortal. D The correlations between the mRNA levels of S6K1 and cell cycle-related genes in BRCA cohort, using data from the GEPIA. E Kaplan-Meier Plotter showing the relapse free survival of patients with breast cancer according to S6K1 mRNA levels

Back to article page

Molecular Cancer

ISSN: 1476-4598